Hillsdale Investment Management Inc. Has $3.63 Million Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Hillsdale Investment Management Inc. lifted its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 0.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 78,000 shares of the company’s stock after purchasing an additional 300 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Twist Bioscience were worth $3,625,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Thrivent Financial for Lutherans lifted its position in Twist Bioscience by 54.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock worth $69,972,000 after purchasing an additional 532,040 shares during the period. State Street Corp raised its stake in shares of Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after buying an additional 526,028 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after acquiring an additional 521,272 shares during the period. Jennison Associates LLC boosted its position in shares of Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after acquiring an additional 302,884 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Twist Bioscience by 63.5% in the fourth quarter. American Century Companies Inc. now owns 756,352 shares of the company’s stock valued at $35,148,000 after acquiring an additional 293,751 shares during the period.

Twist Bioscience Trading Up 2.0 %

Shares of NASDAQ TWST opened at $42.89 on Friday. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The company has a 50-day moving average of $45.40 and a two-hundred day moving average of $45.23. The company has a market cap of $2.56 billion, a PE ratio of -12.69 and a beta of 2.15. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience’s revenue was up 24.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.75) EPS. As a group, equities analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on TWST. JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird boosted their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. Finally, Wolfe Research began coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $54.40.

Insider Activity

In related news, CFO Adam Laponis sold 5,886 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the completion of the sale, the chief financial officer now directly owns 110,096 shares of the company’s stock, valued at $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert Chess sold 5,000 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the completion of the transaction, the director now owns 16,641 shares in the company, valued at $832,050. This represents a 23.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 31,552 shares of company stock valued at $1,500,289 over the last 90 days. 3.01% of the stock is owned by company insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.